Location History:
- Newport, AU (1999 - 2007)
- Williamstown, AU (2009)
- Parkville, AU (2021 - 2022)
Company Filing History:
12 out of 83 
1 out of 525 
Years Active: 1999-2022
Title: The Innovative Mind of Sandra Elaine Nicholson
Introduction
Sandra Elaine Nicholson is a prominent inventor based in Newport, Australia. With a remarkable 13 patents to her name, she has made significant contributions to the field of medical research and therapeutic methods. Her work primarily focuses on the modulation of immune responses, with a particular interest in natural killer (NK) cells.
Latest Patents
One of Sandra's latest patents illustrates her ingenuity in addressing cancer-related conditions. The patent titled "Inhibition of cytokine-induced SH2 protein in NK cells" lays out novel therapeutic and prophylactic methods based on the inhibition of CIS in NK cells. This invention aims to treat or prevent NK-responsive conditions by administering a CIS inhibitor or CIS-inhibited NK cells to a subject. Additionally, it offers methods for identifying a CIS inhibitor and determining the likelihood of a cancer response to treatment with CIS inhibition.
Career Highlights
Throughout her career, Sandra has been associated with esteemed organizations like the Walter and Eliza Hall Institute of Medical Research and Ludwig Institute for Cancer Research Limited. Her dedication to research and innovation has positioned her as a leading figure in the scientific community, making meaningful strides toward better cancer therapies.
Collaborations
Sandra has collaborated with notable peers in the research field, including talented individuals such as Nicos Anthony Nicola and Douglas James Hilton. These collaborations have fostered a rich exchange of ideas and expertise, further enhancing the impact of her work on medical science.
Conclusion
Sandra Elaine Nicholson's commitment to innovation and her impressive portfolio of patents highlight her vital role in advancing our understanding of immune response mechanisms. Her contributions have the potential to improve treatment outcomes for individuals facing NK-responsive conditions, marking her as a significant inventor in her field.